Product Description
Deutetrabenazine is used to treat chorea (sudden movements that you cannot control) caused by Huntington's disease (an inherited disease that causes the progressive breakdown of nerve cells in the brain). It is also used to treat tardive dyskinesia (uncontrollable movement of the face, tongue, or other body parts). Deutetrabenazine is in a class of medications called vesicular monoamine transporter 2 (VMAT2) inhibitors. It works by changing the activity of certain natural substances in the brain that affect nerves and muscles. (Sourced from: https://medlineplus.gov/druginfo/meds/a617022.html)
Mechanisms of Action: VMAT2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Bangladesh | Brazil | Chile | Israel | Korea | United States
Approved Indications: Chorea | Tardive Dyskinesia | Huntington Disease
Known Adverse Events: Tardive Dyskinesia | Huntington Disease | Insomnia | Nasopharyngitis | Pharyngitis | Diarrhea
Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Canada, Denmark, Israel, Italy, Poland, Russia, Slovakia, Spain, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Cerebral Palsy|Dyskinesias|Huntington Disease
Phase 2: Dystonia|Dystonic Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT04713982 | P3 |
Recruiting |
Huntington Disease |
2025-08-01 |
|
| AUDYT | P2 |
Completed |
Dystonia|Dystonic Disorders |
2024-03-15 |
|
| Open RECLAIM-DCP | P3 |
Active, not recruiting |
Cerebral Palsy |
2022-10-16 |
|
| RECLAIM-DCP | P3 |
Completed |
Dyskinesias|Cerebral Palsy |
2022-07-05 |